ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 3.000
+0.080 (2.74%)
Jul 31, 2026, 4:08 PM HKT
HKG:1541 Revenue
In the year 2025, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 154.29M CNY with 108.09% growth. ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 110.28M in the half year ending December 31, 2025, with 1,578.28% growth.
Revenue
154.29M CNY
Revenue Growth
+108.09%
P/S Ratio
7.54
Revenue / Employee
763.83K CNY
Employees
202
Market Cap
1.29B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.29M | 80.15M | 108.09% |
| Dec 31, 2024 | 74.15M | 66.45M | 863.60% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.45B |
| AIM Vaccine | 1.30B |
| Mabpharm | 718.98M |
| Cutia Therapeutics | 374.07M |
| CANbridge Pharmaceuticals | 55.62M |
| Beijing Biostar Pharmaceuticals | 37.13M |
| Zhaoke Ophthalmology | 35.58M |
| SinoMab BioScience | 6.28M |